AbbVie and I-Mab have signed a global collaboration agreement for the development and commercialization of lemzoparlimab (TJC4), an innovative anti-CD47 monoclonal antibody developed by I-Mab for the treatment of multiple cancers. The companies also have the potential to expand the collaboration to additional therapies. AbbVie will pay I-Mab $180 million upfront, along with a $20 million milestone payment based on the Phase I results. I-Mab will be eligible to receive up to $1.74 billion in ...